4.5 Article

Dendrimer-based tumor cell targeting of fibroblast growth factor-1

期刊

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 20, 期 2, 页码 700-703

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2009.11.065

关键词

Dendrimer; Nanotechnology; Fibroblast growth factor; Cancer targeting; Wound healing

资金

  1. National Cancer Institute, National Institutes of Health [R33 CA112141, 1 R21 RR021893]
  2. National Institute of Biomedical Imaging and Bio-Engineering, National Institutes of Health [RO1 EB005028]
  3. National Institute of Diabetes & Digestive & Kidney Diseases [NIH5P60 DK20572]

向作者/读者索取更多资源

Fibroblast Growth Factor Receptor (FGFR) is overexpressed in a wide variety of tumors, and therefore is an attractive target for drug delivery. Recombinant FGF-1 was purified and attached to a fifth-generation (G5) polyamidoamine dendrimer. The specific binding and internalization of this conjugate labeled with FITC was demonstrated by flow cytometry as well as by confocal microscopic analysis in cell lines expressing FGFR. The binding and uptake of FGF-conjugated dendrimers was completely blocked by excess nonconjugated FGF-1. Confocal microscopic analysis showed cytosolic as well as nuclear localization. Multivalent G5-FGF nanoparticles may serve as a platform for cytosolic as well as nuclear drug delivery in tumor cells, and as an FGF delivery agent for angiogenesis and wound healing. Our study shows for the first time the applicability of a dendrimer nanodevice for tumor cell targeting through FGFR. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据